• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of amjphAmerican Journal of Public Health Web SiteAmerican Public Health Association Web SiteSubmissionsSubscriptionsAbout Us
Am J Public Health. 2001 January; 91(1): 42–46.
PMCID: PMC1446500

Sharing of drug preparation equipment as a risk factor for hepatitis C.

Abstract

OBJECTIVES: This study investigated the sharing of drug preparation equipment as a possible route of hepatitis C virus (HCV) transmission. METHODS: HCV seroconversion was measured in a cohort of 317 injection drug users who tested negative for HCV antibody at recruitment. RESULTS: Cumulative HCV incidence was 16.7% per year. Among those who did not share syringes, HCV seroconversion was associated with sharing drug cookers and filtration cotton (adjusted risk ratio = 5.9; 95% confidence interval = 1.1, 31.7); 54% of HCV infections in injection drug users who did not share syringes were attributable to cooker/cotton sharing. CONCLUSIONS: Among injection drug users who do not share syringes, an important proportion of HCV infections may be attributed to cooker/cotton sharing.

Full Text

The Full Text of this article is available as a PDF (84K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Weild AR, Gill ON, Bennett D, Livingstone SJ, Parry JV, Curran L. Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey. Commun Dis Public Health. 2000 Jun;3(2):121–126. [PubMed]
  • Balogun MA, Ramsay ME, Fairley CK, Collins M, Heptonstall J. Acute hepatitis B infection in England and Wales: 1985-96. Epidemiol Infect. 1999 Feb;122(1):125–131. [PMC free article] [PubMed]
  • Crofts N, Aitken CK. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995. Med J Aust. 1997 Jul 7;167(1):17–20. [PubMed]
  • Goldberg D, Cameron S, McMenamin J. Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high. Commun Dis Public Health. 1998 Jun;1(2):95–97. [PubMed]
  • Hagan H, Jarlais DC, Friedman SR, Purchase D, Alter MJ. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health. 1995 Nov;85(11):1531–1537. [PMC free article] [PubMed]
  • Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol. 1999 Feb 1;149(3):203–213. [PubMed]
  • Crofts N, Nigro L, Oman K, Stevenson E, Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users. Addiction. 1997 Aug;92(8):999–1005. [PubMed]
  • van den Hoek JA, van Haastrecht HJ, Goudsmit J, de Wolf F, Coutinho RA. Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam. J Infect Dis. 1990 Oct;162(4):823–826. [PubMed]
  • Chamot E, de Saussure P, Hirschel B, Déglon JJ, Perrin LH. Incidence of hepatitis C, hepatitis B and HIV infections among drug users in a methadone-maintenance programme. AIDS. 1992 Apr;6(4):430–431. [PubMed]
  • Van Ameijden EJ, Van den Hoek JA, Mientjes GH, Coutinho RA. A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. Eur J Epidemiol. 1993 May;9(3):255–262. [PubMed]
  • Crofts N, Hopper JL, Bowden DS, Breschkin AM, Milner R, Locarnini SA. Hepatitis C virus infection among a cohort of Victorian injecting drug users. Med J Aust. 1993 Aug 16;159(4):237–241. [PubMed]
  • Levine OS, Vlahov D, Nelson KE. Epidemiology of hepatitis B virus infections among injecting drug users: seroprevalence, risk factors, and viral interactions. Epidemiol Rev. 1994;16(2):418–436. [PubMed]
  • Esteban JI, López-Talavera JC, Genescà J, Madoz P, Viladomiu L, Muñiz E, Martin-Vega C, Rosell M, Allende H, Vidal X, et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med. 1991 Sep 15;115(6):443–449. [PubMed]
  • Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol. 1999 Feb 1;149(3):203–213. [PubMed]
  • van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study. BMJ. 1998 Aug 15;317(7156):433–437. [PMC free article] [PubMed]
  • Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18 (Suppl 1):S11–S19. [PubMed]
  • Hagan H, Jarlais DC, Friedman SR, Purchase D, Alter MJ. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health. 1995 Nov;85(11):1531–1537. [PMC free article] [PubMed]
  • Rezza G, Sagliocca L, Zaccarelli M, Nespoli M, Siconolfi M, Baldassarre C. Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence. Scand J Infect Dis. 1996;28(1):27–29. [PubMed]
  • Des Jarlais DC. The first and second decades of AIDS among injecting drug users. Br J Addict. 1992 Mar;87(3):347–353. [PubMed]
  • Grund JP, Friedman SR, Stern LS, Jose B, Neaigus A, Curtis R, Des Jarlais DC. Syringe-mediated drug sharing among injecting drug users: patterns, social context and implications for transmission of blood-borne pathogens. Soc Sci Med. 1996 Mar;42(5):691–703. [PubMed]
  • Cole P, MacMahon B. Attributable risk percent in case-control studies. Br J Prev Soc Med. 1971 Nov;25(4):242–244. [PMC free article] [PubMed]
  • Shah SM, Shapshak P, Rivers JE, Stewart RV, Weatherby NL, Xin KQ, Page JB, Chitwood DD, Mash DC, Vlahov D, et al. Detection of HIV-1 DNA in needle/syringes, paraphernalia, and washes from shooting galleries in Miami: a preliminary laboratory report. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Mar 1;11(3):301–306. [PubMed]
  • Jose B, Friedman SR, Neaigus A, Curtis R, Grund JP, Goldstein MF, Ward TP, Des Jarlais DC. Syringe-mediated drug-sharing (backloading): a new risk factor for HIV among injecting drug users. AIDS. 1993 Dec;7(12):1653–1660. [PubMed]
  • Stark K, Müller R, Bienzle U, Guggenmoos-Holzmann I. Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin. AIDS. 1996 Mar;10(3):311–317. [PubMed]
  • Greenland S. Response and follow-up bias in cohort studies. Am J Epidemiol. 1977 Sep;106(3):184–187. [PubMed]
  • Vlahov D, Astemborski J, Solomon L, Nelson KE. Field effectiveness of needle disinfection among injecting drug users. J Acquir Immune Defic Syndr. 1994 Jul;7(7):760–766. [PubMed]
  • Titus S, Marmor M, Des Jarlais D, Kim M, Wolfe H, Beatrice S. Bleach use and HIV seroconversion among New York City injection drug users. J Acquir Immune Defic Syndr. 1994 Jul;7(7):700–704. [PubMed]

Articles from American Journal of Public Health are provided here courtesy of American Public Health Association

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...